Allarity Therapeutics is progressing with Phase 3 manufacturing of stenoparib, a dual PARP and WNT pathway inhibitor, aiming to complete by Q3 2026. This step supports a pivotal trial for advanced ovarian cancer, leveraging FDA Fast Track designation to accelerate approval. The company has completed all manufacturing payments and expects no further costs. Ongoing Phase 2 trials continue enrolling patients, with plans to advance toward pivotal-stage clinical development soon.
The FDA has granted traditional approval to Fabhalta (iptacopan), a first-in-class complement inhibitor, for slowing kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN). Fabhalta showed a 48% slower decline in kidney fu...
Corbin Advisors' Q2 2026 survey shows industrial investor sentiment at its highest in five years, with 84% of participants bullish or neutral-to-bullish due to strong order momentum and demand from data centers and AI sectors. Expectations for Q2 rev...
Dogecoin (DOGE) remains stuck near recent lows around $0.0737, trading below major moving averages which signals a continuing downtrend. The price faces resistance at $0.0765 and stronger barriers up to $0.1057, making a bullish reversal challenging....
CASHCAT cryptocurrency remains under strong selling pressure, unable to recover past key resistance levels between $0.125 and $0.133. The token has stabilized near $0.10 but continues to show a bearish trend with lower highs and lows since its peak a...
Cronos (CRO) surged 7.43% to $0.0597, leading gains among altcoins due to strategic partnerships and ecosystem growth. Other notable gainers included Beldex, Stable, Mantle, and Polkadot, each rising between 2% and 6%. Conversely, Lighter fell 10.43%...
